

1  
2  
3

MYOFASCIAL PAIN (R GERWIN, SECTION EDITOR)

4

**Physiologic Effects of Dry Needling**

5

**Barbara Cagnie · Vincent Dewitte · Tom Barbe ·**

6

**Frank Timmermans · Nicolas Delrue · Mira Meeus**

7

© Springer Science+Business Media New York 2013

9

**Abstract** During the past decades, worldwide clinical and scientific interest in dry needling therapy has grown exponentially. Various clinical effects have been credited to dry needling, but rigorous evidence about its potential physiological mechanisms of actions and effects is still lacking. Research identifying these exact mechanisms of dry needling action is sparse and studies performed in an acupuncture setting do not necessarily apply to DN. The studies of potential effects of DN are reviewed in reference to the different aspects involved in the pathophysiology of myofascial triggerpoints: the taut

band, local ischemia and hypoxia, peripheral and central sensitization. This article aims to provide the physiotherapist with a greater understanding of the contemporary data available: what effects could be attributed to dry needling and what are their potential underlying mechanisms of action, and also indicate some directions at which future research could be aimed to fill current voids.

10

**Keywords** Myofascial trigger point · Myofascial pain syndrome · Dry needling · Sensitization · Physiological Effects · Pain physiology

11

12

13

14

15

16

17

18

This article is part of the Topical Collection on *Myofascial Pain*

B. Cagnie (✉) · V. Dewitte · T. Barbe · M. Meeus  
 Department of Rehabilitation sciences and Physiotherapy, Ghent University, De Pintelaan 185 3B3,  
 9000 Ghent, Belgium  
 e-mail: barbara.cagnie@ugent.be

V. Dewitte  
 e-mail: vincent.dewitte@ugent.be

T. Barbe  
 e-mail: tom.barbe@ugent.be

M. Meeus  
 e-mail: mira.meeus@ua.ac.be  
 e-mail: mira.meeus@ugent.be

F. Timmermans  
 Uplands Physiotherapy Clinic, #121-725 Carmi Avenue,  
 Penticton, B.C., Canada V2A 3G8  
 e-mail: uplandspysio@shaw.ca  
 URL: [www.dryneedling.nl](http://www.dryneedling.nl)

N. Delrue  
 Normandiëstraat 186,  
 8560 Wevelgem, Belgium  
 e-mail: delruenicolas@telenet.be

M. Meeus  
 "Pain in Motion" research group, Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium

**Introduction** 29

Myofascial pain syndrome (MPS) is a common diagnosis in patients with musculoskeletal pain associated with active and latent myofascial trigger points (MTrPs). A MTrP is defined as a hyperirritable spot in a taut band of skeletal muscle fibers. An active MTrP has spontaneous pain or pain in response to movement, stretch or compression, while a latent MTrP is a sensitive spot with pain or discomfort in response to compression only [1, 2]. The literature suggests several treatment interventions to treat MTrPs: dry needling therapy (DN) being one of them [3]. DN uses a fine, solid filiform needle and is also known as intramuscular stimulation.

During the past decades, clinical and scientific interest in DN has grown exponentially and various treatment effects are being credited to DN, such as: decreased pain and muscle tension, improved range of motion, muscle strength and coordination. However, there is still little scientific backup. A recent systematic review of Tough et al. concluded that there is limited evidence derived from one study that deep needling directly into myofascial trigger points has an overall treatment effect, when compared with standardized care [4]. Kim et al. [5] conclude that, despite the positive results of individual studies, the level of evidence supporting the efficacy and effectiveness

52 of DN for several conditions remains insufficient, because of  
 53 concerns about a lack of precision and a high risk of  
 54 bias of the studies. Rigorous large-scale, placebo con-  
 55 trolled, clinical trials are needed to evaluate the clinical  
 56 utility of this technique [4, 5•].

57 This article reviews the current state of knowledge of phys-  
 58 iologic effects of DN by an in-depth review of basic and clinical  
 59 research that has been published. First, a general overview of  
 60 pain pathways and modulation of the pain perception is pro-  
 61 vided, as this should be the basis and reasonable rationale for all  
 62 therapeutic interventions, including DN. Second, after giving a  
 63 short overview of the pathophysiology of MTrPs, the different  
 64 underlying mechanisms of DN are described in reference to the  
 65 different aspects involved in the pathophysiology of MTrPs.  
 66 These findings are then critically discussed.

67 We hope to provide the therapist with a better under-  
 68 standing of the contemporary data available and what effects  
 69 could be attributed to DN, what their potential underlying  
 70 mechanisms of action are and the directions that future  
 71 research could be aimed at to fill in the current voids.

72 **Pain Physiology**

73 Pain sensations originate mainly in two types of pain recep-  
 74 tors: low-threshold nociceptors that are connected to fast  
 75 conducting  $\alpha\delta$ -fibers, and high-threshold nociceptors that con-  
 76 duct impulses through slower unmyelinated C-fibers. Central  
 77 terminals of these sensory fibers enter the central nervous  
 78 system (CNS) through the dorsal horn of the spinal cord,  
 79 where they connect with spinal neurons via synaptic transmis-  
 80 sion. Neurons of superficial laminae I and deep laminae V  
 81 project along the spinothalamic and spinoreticulothalamic  
 82 tracts to supraspinal sites such as the thalamus, parabrachial  
 83 nucleus, and amygdala, where pain signals are further  
 84 processed and sent on to higher cortical centers [6].

85 **Peripheral Pain Modulation**

86 Peripheral activation of  $A\delta$ - and C-fibre nociceptors is mod-  
 87 ulated by a number of sensitizing and algogenic agents, such  
 88 as substance P (SP), bradykinin, histamine, calcitonin gene-  
 89 related peptide (CGRP), prostaglandins, interleukin- $1\beta$   
 90 (IL $1\beta$ ), tumor necrosis factor (TNF), and nerve growth  
 91 factor (NGF). All of these can be released following cellular  
 92 damage [6]. The local release of some of these chemicals  
 93 (SP, histamine) causes inflammation and vasodilation, con-  
 94 tributing to the “protective” function of pain [6, 7].

95 **Central Pain Modulation**

96 The sensation of pain is not only subject to modulation  
 97 during its ascending transmission from the periphery to the

cortex, but also to spinal modulation and descending control 98  
 from higher neurological centres. 99

100 An important mechanism in the modulation of pain per-  
 101 ception is *segmental inhibition*, which is the modified “gate  
 102 theory of pain control”, first published by Melzack and Wall  
 103 in 1965. This hypothesis describes how activation of  $A\beta$ -  
 104 fibres can lead to an inhibition in the spinal cord by blocking  
 105 the synaptic transmission between the  $A\delta$ - and C-fibres and  
 106 the cells in the dorsal horn, because of the slower informa-  
 107 tion transmission of the latter [6].

108 Another possible mechanism of pain modulation is  
 109 through the *endogenous opioid system*. It is well known that  
 110 the three main groups of opioid peptides:  $\beta$ -endorphin,  
 111 enkephalins and dynorphines, and their  $\mu$ -,  $\delta$ - and  $\kappa$ -  
 112 receptors are widely distributed in peripheral primary affer-  
 113 ent terminals and areas of the central nervous systems relat-  
 114 ed to nociception [6]. The analgesic effects of opioids arise  
 115 from their ability to inhibit directly the ascending transmis-  
 116 sion of nociceptive information from the spinal cord dorsal  
 117 horn. They are also able to activate pain control circuits that  
 118 descend from the midbrain [periaqueductal gray (PAG)], via  
 119 the rostral ventromedial medulla (RVM) to the spinal cord  
 120 dorsal horn [7].

121 Besides the endogenous opioids as important neurotrans-  
 122 mitters in the descending pain control system, *serotonin* (5-  
 123 *HT*) and *noradrenaline* are the two other, most familiar and  
 124 well investigated, transmitters of this pathway. However,  
 125 descending projections containing dopamine (monoamine)  
 126 and many other neurotransmitters can also play a crucial  
 127 role in pain modulation [8].

128 **Chronic Pain—Central Sensitization**

129 In conditions with chronic pain, the balance in pain modu-  
 130 lation can be disturbed due to impaired pain inhibition  
 131 and/or enhanced pain facilitation. This may lead to  
 132 “centralsensitization”. Central sensitization entails altered  
 133 sensory processing in the brain, increased spontaneous ac-  
 134 tivity of dorsal horn neurons, dysfunctional endogenous  
 135 analgesia, expansion of receptive field sizes, reduction in  
 136 threshold, prolonged after-discharges, and increased activity  
 137 of brain-orchestrated facilitatory pathways, which augment  
 138 nociceptive transmission [8–12]. Central sensitization re-  
 139 sults in enhanced nociception (hyperalgesia) and pain elic-  
 140 ited by normally non-noxious stimuli (allodynia) [7, 12].

141 Also, altered states of diffuse noxious inhibitory control  
 142 (DNIC) have been associated with central sensitization in  
 143 chronic pain patients [13–15]; often now referred to as  
 144 “conditioned pain modulation” (CPM). CPM is a “pain-in-  
 145 hibits-pain” paradigm and occurs when two noxious stimuli  
 146 are applied heterotopically, i.e., a second nociceptive stim-  
 147 ulus is applied in a more remote location, outside the recep-  
 148 tive field of the first. This second nociceptive stimulus (such

149 as heat, high pressure or electric stimulation) will be  
 150 processed by the dorsal horn wide dynamic range neurons  
 151 and can lead to inhibition of the first one.

152 Central sensitization can also be enhanced and  
 153 maintained by supraspinal processes involving cognitions,  
 154 attention, emotions and motivation. These forebrain prod-  
 155 ucts can make a significant contribution to the clinical pain  
 156 experience in, e.g., MPS and are referred to as cognitive  
 157 emotional sensitization [16–18].

158 **Pathophysiology of MTrPs**

159 In order to understand the underlying mechanisms of DN,  
 160 some knowledge of the pathophysiology of MTrPs is help-  
 161 ful [1, 2]. The most credited local hypothesis for primary  
 162 MTrP formation is the hypothesis first put forward by  
 163 Simons et al. [19] and later expanded by Gerwin et al. [20].

164 They suggest that the first phase of trigger point forma-  
 165 tion consists of the *development of a taut band* as a result of  
 166 abnormal endplate potential caused by excessive acetylcho-  
 167 line (ACh) release in the neuromuscular junction at the  
 168 motor endplates [19, 21••]. EMG studies show this as  
 169 ‘spontaneous electrical activity’ (SEA), also called ‘endplate  
 170 noise’. MTrP irritability can be objectively assessed with the  
 171 prevalence or amplitude changes of SEA that are recorded in  
 172 this region [22].

173 It is further hypothesized that, due to this excessive ACh  
 174 release at the motor endplate, sustained sarcomere contrac-  
 175 tures occur, that could lead to *local ischemia and hypoxia*.  
 176 Consequently, vasoactive and algogenic substances are re-  
 177 leased that can sensitize peripheral nociceptors (*peripheral*  
 178 *sensitization*). Sustained peripheral nociceptive input might  
 179 sensitize dorsal horn neurons and supraspinal structures,  
 180 leading to hyperalgesia and allodynia, as well as referred  
 181 pain (*central sensitization*) [21••, 23–25].

182 **Physiological Effects of Dry Needling**

183 There is some emerging DN research, but the exact mech-  
 184 anisms of action of direct needling in the deactivation of  
 185 trigger points are not yet unraveled. Also, most of our  
 186 current understanding of the systemic physiologic effects  
 187 of DN is (in)directly derived from acupuncture literature  
 188 [26••, 27••, 28]. Indeed, there are some similarities between  
 189 acupuncture and DN, but, more importantly, many signifi-  
 190 cant differences. Not just in the underlying philosophies and  
 191 explanation models, but also in the ‘technical’ details: one  
 192 of more needles applied, the movement of the needle, the  
 193 depth of needle insertion, the amount and force of stimula-  
 194 tion and the elicitation of a ‘local twitch response’ (LTR). A  
 195 LTR is an involuntary spinal reflex resulting in a localized

196 contraction of affected muscle fibers that are being manually  
 197 stretched, injected or dry needled. According to Hong et al.  
 198 [29], DN is most effective when these LTRs are elicited.

199 Clinical results from Ceccherelli et al. [30] demonstrated  
 200 that deep stimulation had a better analgesic effect when  
 201 compared with superficial stimulation. It seems obvious to  
 202 expect different results from superficial or deeper insertion.  
 203 Deeper insertion of the needle affects several structures:  
 204 skin, fascia, and muscle layers, whereas superficial insertion  
 205 affects merely the skin and some superficial layers. Itoh et  
 206 al. [31] have demonstrated this principle in several other  
 207 studies, too, and conclude that the depth of needle penetra-  
 208 tion is important for the relief of muscle pain.

209 The potential effects of DN will now be reviewed in  
 210 reference to the four different aspects involved in the path-  
 211 ophysiology of MTrPs: the taut band, local ischemia and  
 212 hypoxia, peripheral and central sensitization. An overview  
 213 of the potential DN physiological effects is shown in Fig. 1.


214 **Effects on the Taut Band**

215 A statement that is often found in MPS papers and textbooks  
 216 is “the effectiveness of DN probably lies in the mechanical  
 217 disruption of the integrity of dysfunctional endplate”[19, 32].  
 218 To the best of our knowledge, basic research has not yet  
 219 demonstrated an actual mechanical disruption of the endplate  
 220 in recent studies.

221 It has been demonstrated that DN may influence the SEA  
 222 by eliciting a LTR. Both Chen et al. [33] and Hsieh et al.  
 223 [34] demonstrated in their studies that DN to a MTrP region  
 224 could effectively suppress SEA, when LTRs were elicited.  
 225 They suggest that the insertion of a needle at the endplate  
 226 region may lead to increased discharges and thereby imme-  
 227 diately reduce available ACh stores, leading to a lesser SEA.  
 228 Another working mechanism could be that sufficient me-  
 229 chanical needling activation around the endplate area causes  
 230 muscle fibers to discharge and thus elicit a LTR. Baldry [35]  
 231 mentioned that a LTR causes alterations in the length and  
 232 tension of the muscle fibers and stimulates mechanorecep-  
 233 tors like the Aβ-fibers.

234 **Effects on Blood Flow**

235 As previously mentioned, sustained contractures of taut  
 236 muscle bands might cause local ischemia and hypoxia in  
 237 the core of the MTrPs. Different studies have demon-  
 238 strated that needling may increase muscle blood flow and  
 239 oxygenation [36–42]. Several mechanisms have been  
 240 suggested to explain the local muscle response of blood  
 241 flow in needle stimulation. The most plausible one is the  
 242 release of vasoactive substance, such as CGRP and SP  
 243 which, upon activation of Aδ- and C-fibers via the axon



**Fig. 1** Schematic diagram of the potential physiological effects of DN.

244 reflex, leads to vasodilatation in small vessels and in- 264  
 245 creased blood flow [43]. 265

246 There is a discrepancy in the literature whether this 266  
 247 increase in blood flow is restricted to the needling site or 267  
 248 if vasodilatation and increases in blood flow also extend 268  
 249 beyond the site of stimulation (see “remote effects”). Some 269  
 250 studies have demonstrated remote circulatory effects with 270  
 251 needling [37], whereas others did not show an increase in 271  
 252 blood flow at distant sites of the needling [36, 42]. Sandberg 272  
 253 et al. [37] did find a transient significant increase in contra- 273  
 254 lateral blood flow in the trapezius muscle after needle stim- 274  
 255 ulation. However, this increase was significantly less than in 275  
 256 the stimulated muscle and apparently only there for the first 276  
 257 two minutes after the needle stimulation. 277

258 In a recent study by Hsieh et al. [44••] they found an 278  
 259 increase in a number of hypoxic-responsive proteins, includ- 279  
 260 ing hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ), inducible iso- 280  
 261 form of nitric oxide synthases (iNOS) and vascular endo- 281  
 262 thelial growth factor (VEGF) production in the biceps 282  
 263 femoris muscle after DN stimulation. These proteins can 283

264 promote angiogenesis, vasodilation, and altered glucose 264  
 265 metabolism in hypoxic tissues. Repeated localized DN 265  
 266 may thus upregulate the expression of HIF-1, iNOS, and 266  
 267 VEGF proteins, and potentially increase capillarity in the 267  
 268 skeletal muscle and improve the circulation in muscles 268  
 269 containing MTrPs. However, long(er) term follow-up stud- 269  
 270 ies are needed as the effects on circulation beyond 5 days 270  
 271 remain unclear. 271

272 Neurophysiological Effects: Effects on Peripheral 272  
 273 Sensitization 273

274 Shah et al. [45, 46] found that the concentrations of SP and 274  
 275 CGRP were higher in the vicinity of active MTrPs compared 275  
 276 to latent ones or normal muscle tissue. After a LTR was 276  
 277 elicited, SP and CGRP concentrations were significantly 277  
 278 lowered compared to their pre-LTR values. These results were 278  
 279 consistent with the data of Hsieh et al. [44••]. The data 279  
 280 obtained from their study showed that a single session treat- 280  
 281 ment produced a short-term analgesic effect by decreasing the 281

282 SP at peripheral sites, however, no lasting effect was observed  
 283 5 days after DN. In contrast, five consecutive sessions (one per  
 284 day) of DN, increased the SP levels immediately after the need-  
 285 ling and was maintained 5 days after the DN. This was accom-  
 286 panied by higher levels of TNF- $\alpha$ , iNOS, HIF-1, COX-2 and  
 287 VEGF. Studies have demonstrated that increased COX-2 and  
 288 TNF levels are associated with muscle damage [47]. It is likely  
 289 that the five sessions of DN accumulated to an excessive level of  
 290 intramuscular manipulation and caused damage in the fibers with  
 291 noxious inputs (C-fibers) and increased release of SP.

292 Secondly, peripheral opioid analgesia has received con-  
 293 siderable attention as an endogenous pathway of inhibiting  
 294 pain, mainly in the acupuncture literature, although clear  
 295 mechanisms remain elusive. Hsieh et al. [44••] have also  
 296 shown that increased  $\beta$ -endorphin levels can suppress neu-  
 297 rons from releasing SP and thus inhibit pain transmission  
 298 [44••]. Using an animal model, they demonstrated that one  
 299 session of DN in the biceps femoris enhanced the beta-  
 300 endorphin levels in the biceps muscle and serum immedi-  
 301 ately after needling, but no lasting effect was observed  
 302 5 days after the needling. In contrast, the five consecutive  
 303 sessions of DN reversed this effect.

304 **Neurophysiological Effects: Effects on Central Sensitization**

305 According to Chou et al. [26••], the most likely mechanism  
 306 of pain relief through needle stimulation is hyperstimulation  
 307 analgesia, which was originally proposed by Melzack [48].  
 308 DN may stimulate, both large myelinated fibers (i.e., A $\beta$ -  
 309 and A $\delta$ -fibers), as well as C-fibers, indirectly via the release  
 310 of inflammatory mediators. As a result of mechanical stimu-  
 311 lation, A $\beta$ - and A $\delta$ -fibers are both activated and send  
 312 afferent signals to the dorsolateral tracts of the spinal cord  
 313 and could activate the supraspinal and higher centres in-  
 314 volved in pain processing. Different mechanisms can occur,  
 315 either in isolation or concurrently.

316 **Segmental Inhibition/Gate Control**

317 Chu [49] stated that, when a needle is rapidly thrust into a  
 318 MTrP, the LTRs evoked lead to a large diameter-sensory  
 319 afferent proprioceptive input into the spinal cord. This could  
 320 have a “gate-controlling” effect of blocking the intra-dorsal  
 321 horn passage of noxious information generated in the  
 322 MTrP’s nociceptors.

323 Srbely et al. [50] identified an immediate increase in the  
 324 pain pressure threshold (PPT) at the infraspinatus MTrP,  
 325 compared with the gluteus medius point, at 3 and 5 minutes  
 326 after DN the infraspinatus muscle. They hypothesized that  
 327 site-specific DN may be mediated by segmental inhibitory  
 328 effects, evoked by selective stimulation of large myelinated  
 329 fibers in the MTrP.

It has been proposed that “satellite or secondary” MTrPs 330  
 may develop in the referred pain zone from “key or prima- 331  
 ry” MTrPs. Hsieh et al. [51] conducted a clinical study and 332  
 provided evidence that DN-evoked inactivation of a primary 333  
 (key) MTrP inhibited the activity in ipsilateral secondary 334  
 (satellite) MTrPs situated in its referral pain zone. Ferandez- 335  
 Carnero et al. [52] showed that an increased nociceptive 336  
 activity at latent MTrPs in the infraspinatus muscle in- 337  
 creased motor activity and sensitivity of a MTrP in distant 338  
 muscles connected to the same segmental level. 339

*Release of Endogenous Opioids* 340

Knowledge of the central effects of DN upon opioid release 341  
 is limited. Using functional magnetic resonance imaging, 342  
 Niddam et al. [53] showed that pain following the insertion 343  
 of a needle into a trigger point, combined with electrical 344  
 stimulation, is mediated through the PAG in the brainstem. 345  
 The PAG is a central part of the opioid circuitry that controls 346  
 nociceptive transmission at the level of spinal cord and 347  
 cortex [8]. The change in PAG-activity was correlated with 348  
 the change in PPT. It is hypothesized that DN, via stimula- 349  
 tion of the nociceptive fibers, may activate the 350  
 enkephalinergic inhibitory dorsal horn interneurons. It is 351  
 unclear whether the needle manipulation or the electrical 352  
 stimulation is responsible for these results or both. This 353  
 combination, being “electro-acupuncture”, is also men- 354  
 tioned in clinical studies on acupuncture-induced analgesia 355  
 and laboratory results report endogenous opiate peptides to 356  
 be involved. 357

*Effect on the Release of Neurotransmitters: Serotonin 358  
 and Noradrenaline* 359

Stimulation of A $\delta$ -nerve fibers may also activate the sero- 360  
 tonergic and noradrenergic descending inhibitory system. 361  
 Although there are no known specific experimental or clin- 362  
 ical studies supporting the proposed serotonergic and nor- 363  
 adrenergic mechanisms of DN, it is hypothesized that DN 364  
 may have an effect on both systems, often based again on 365  
 acupuncture literature [27••]. 366

Shah et al. [45, 46] found that the concentration of 5-HT 367  
 and noradrenaline, was higher in the vicinity of active 368  
 MTrPs compared to latent MTrP or normal muscle tissue. 369  
 5-HT receptors are primarily pronociceptive in the periph- 370  
 ery, acting directly on afferent nerves and indirectly by 371  
 release of other mediators (e.g., SP and glutamate). 372

*Conditioned Pain Modulation* 373

Patients with chronic musculoskeletal pain have impaired 374  
 CPM. Depressed CPM will lead to a reduction of endoge- 375  
 nous pain inhibition and can contribute to a chronic pain 376

377 state [13]. Several reviews have hypothesized that needling  
 378 may affect CPM [27••]. However, recent findings in both  
 379 healthy and whiplash-patients have demonstrated that CPM  
 380 on temporal summation of pressure pain did not respond to  
 381 acupuncture needling [54, 55].

382 *Remote Effects*

383 Different studies have investigated the remote effects of DN,  
 384 both ‘distal to proximal’ effects and contralateral effects.  
 385 Tsai et al. [56] and Fu et al. [22] both found that DN of a  
 386 distal MTrP could provide a remote effect to reduce the  
 387 irritability of a proximal MTrP. The literature is conflicting  
 388 with respect to contralateral effects. Hsieh et al. [34] did find  
 389 contralateral effects in an animal study, whereas Fu et al.  
 390 [22] did not find these.

391 The neural pathway for the remote effects appears to be  
 392 mediated via a spinal reflex, which depends on an intact  
 393 afferent pathway from the remote stimulating site to the  
 394 spinal cord and normal spinal cord function at the level  
 395 corresponding to the innervations of the proximally affected  
 396 muscle [34]. It is further hypothesized that the remote ef-  
 397 fects may relate to a consequence of CPM, but firm evi-  
 398 dence is lacking [26••].

399 *Placebo Effects*

400 It is well known that expectation can significantly modulate  
 401 pain perception, a mechanism frequently referred to as pla-  
 402 cebo analgesia [57]. Neuroimaging data demonstrate that  
 403 placebo analgesia recruits subcortical and opioid sensitive  
 404 brain regions, also involved in pain perception (including  
 405 PAG, rostral anterior cingulate cortex, thalamus, insula,  
 406 amygdala, and in some studies the prefrontal cortex).  
 407 Many of these areas overlap with those modulated by nee-  
 408 dling. Functional magnetic resonance studies have con-  
 409 firmed that expectancy can influence acupuncture analgesia  
 410 [58]. Obviously, placebo effects have to be considered when  
 411 designing and conducting DN studies.

412 **Discussion**

413 DN has become a popular treatment technique with an  
 414 increasing amount of studies demonstrating its clinical ef-  
 415 fects. Rigorous evidence about its physiological mecha-  
 416 nisms of actions and effects is needed now in order to start  
 417 supporting it as evidence based practice. The difficult meth-  
 418 odological characteristics related to experimental studies  
 419 and the complex network in pathological conditions may  
 420 certainly account for this lack of research so far.

421 Direct comparison between existing needling studies is  
 422 difficult as the intervention parameters vary considerably

with respect to the methodological characteristics. It seems  
 logical that mechanisms and effects of DN actions differ  
 depending on: the location(s) of the needle placement(s), the  
 depth of the insertion(s), the needle forces and motions  
 used, and whether or not a LTR is elicited [59].

Most recommended clinical and research parameters are  
 based on experts’ opinions. Recently, Davis et al. [60••]  
 have developed an innovative device to quantify needling  
 motion and force parameters in a treatment-like setting.  
 Needling data can then subsequently be analyzed, providing  
 a more objective method for characterizing needling in basic  
 and clinical needling research. Studies are needed to identify  
 optimal intervention parameters for DN.

Further insights into the MPS’ pathophysiology mecha-  
 nisms are welcomed, in order to find out more how pain  
 modulation systems are being affected by it. Most of the  
 existing studies on needling analgesia have focused on  
 physiological pain in “normal” animals and human volun-  
 teers. However, current evidence points to far more complex  
 pain mechanisms, especially in chronic pain patients. To  
 better explore the mechanisms of analgesia, adequate  
 models of chronic pain should be developed and applied  
 in research. This may prevent scientists from an overexcited  
 search for DN effects and explanation models, which might  
 not be applicable given the complex modified circumstances  
 in ‘real’ patients.

When chronic pain and central sensitization are present,  
 there is an increased responsiveness to a variety of peripheral  
 stimuli. A general recommendation in these patients is to  
 increase pain during treatment, as any therapeutic intervention  
 could serve as a new peripheral source of nociceptive barrage  
 sustaining the process of central sensitization [12, 61].

DN activates several types of receptors, including  
 nociceptors, and daily practice shows it is not always well  
 tolerated in patients with central sensitization and therefore  
 may not be a suitable choice. In a recent educational re-  
 source paper, published by the American Physical Therapy  
 Association (February 2013), it is highlighted that severe  
 hyperalgesia or allodynia may interfere with the application  
 of DN. However, it should not be considered as an absolute  
 contraindication. Several authors suggest in their reviews  
 that treatment of concurrent MTrPs in, e.g., fibromyalgia  
 should be systematically performed before any specific fi-  
 bromyalgia therapy is undertaken [32]. Their idea is that any  
 peripheral source of nociception should be removed before  
 desensitization of the central nervous system can become  
 the focus of the therapy.

**Conclusions**

We can conclude, after reviewing the current basic science  
 findings, that the physiological mechanisms and effects of

473 DN are highly complex and recruit central and peripheral  
474 networks with physiologic and psychological responses.

475 Results from studies performed in an acupuncture setting  
476 do not necessarily pertain to DN.

477 Further insight in MPS and its pathophysiological mech-  
478 anisms are needed, as well as studies investigating the exact  
479 biomechanical and neurophysiological mechanisms of ac-  
480 tion of DN in order to support its clinical evidence. To better  
481 explore the DN mechanisms of analgesia, adequate models  
482 of chronic pain should be developed and applied in research.

483 There is still a long road ahead before the clinician has a  
484 well-constructed, evidence-based explanation model of DN.  
485 We hope this review will stimulate researchers to further  
486 explore the mechanisms and physiological effects of DN by  
487 conducting experiments that are both methodologically  
488 sound and clinically relevant.  
489

490 **Compliance with Ethics Guidelines**

491 **Conflict of Interest** Dr. Barbara Cagnie reported no potential con-  
492 flicts of interest relevant to this article.

493 Dr. Vincent Dewitte reported no potential conflicts of interest  
494 relevant to this article.

495 Dr. Tom Barbe reported no potential conflicts of interest relevant to  
496 this article.

497 Dr. Frank Timmermans reported no potential conflicts of interest  
498 relevant to this article.

499 Dr. Nicolas Delrue reported no potential conflicts of interest rele-  
500 vant to this article.

501 Dr. Mira Meeus reported no potential conflicts of interest relevant  
502 to this article.

504 **Human and Animal Rights and Informed Consent** This article  
505 does not contain any studies with human or animal subjects performed  
506 by any of the authors.  
507

508 **References**

509 Papers of particular interest, published recently, have been  
510 highlighted as:

- 511 • Of importance
- 512 •• Of major importance

513 1. Hong CZ. Treatment of myofascial pain syndrome. *Curr Pain*  
514 *Headache Rep.* 2006;10(5):345–9.

515 2. Kuan TS. Current studies on myofascial pain syndrome. *Curr Pain*  
516 *Headache Rep.* 2009;13(5):365–9.

517 3. • Vulfsons S, Ratmansky M, Kalichman L. Trigger point needling:  
518 techniques and outcome. *Curr Pain Headache Rep.*  
519 2012;16(5):407–12. *In this review the authors provide an excellent*  
520 *update on last years' advancements in basic science, imaging*  
521 *methods, efficacy, and safety of dry needling of MTrPs.*

522 4. Tough EA, White AR, Cummings TM, et al. Acupuncture and dry  
523 needling in the management of myofascial trigger point pain: a  
524 systematic review and meta-analysis of randomised controlled tri-  
525 als. *Eur J Pain.* 2009;13(1):3–10.

526 5. • Kim TH, Lee CR, Choi TY, et al. Intramuscular stimulation  
527 therapy for healthcare: a systematic review of randomised con-  
528 trolled trials. *Acupunct Med.* 2012;30(4):286–90. *A total of 416*  
529 *publications were initially collected and only 4 studies could be*  
530 *included in this review. This is showing the urgent need of rigorous*  
531 *large-scale clinical trials on dry needling.*

532 6. Patel N. Physiology of pain. In: Patel N, Kopf A, editors. *Guide to*  
533 *pain management in low-resource settings.* 2010. p. 13–18.

534 7. Ossipov MH. The perception and endogenous modulation of pain.  
535 *Scientifica.* 2012;1–25.

536 8. Millan MJ. Descending control of pain. *Prog Neurobiol.*  
537 2002;66(6):355–474.

538 9. Li J, Simone DA, Larson AA. Windup leads to characteristics of  
539 central sensitization. *Pain.* 1999;79(1):75–82.

540 10.Coderre TJ, Katz J, Vaccarino AL, et al. Contribution of central  
541 neuroplasticity to pathological pain: review of clinical and exper-  
542 imental evidence. *Pain.* 1993;52(3):259–85.

543 11. Staud R, Craggs JG, Robinson ME, et al. Brain activity  
544 related to temporal summation of C-fiber evoked pain. *Pain.*  
545 2007;129(1–2):130–42.

546 12. Nijs J, Van Houdenhove B, Oostendorp RA. Recognition of central  
547 sensitization in patients with musculoskeletal pain: Application of  
548 pain neurophysiology in manual therapy practice. *Man Ther.*  
549 2010;15(2):135–41.

550 13. Yarnitsky D. Conditioned pain modulation (the diffuse noxious  
551 inhibitory control-like effect): its relevance for acute and chronic  
552 pain states. *Curr Opin Anaesthesiol.* 2010;23(5):611–5.

553 14. Meeus M, Nijs J, Van de Wauwer N, et al. Diffuse noxious  
554 inhibitory control is delayed in chronic fatigue syndrome: an  
555 experimental study. *Pain.* 2008;139(2):439–48.

556 15. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. *J*  
557 *Clin Invest.* 2010;120(11):3779–87.

558 16. Zusman M. Forebrain-mediated sensitization of central pain path-  
559 ways: 'non-specific' pain and a new image for MT. *Man Ther.*  
560 2002;7(2):80–8.

561 17. Brosschot JF. Cognitive-emotional sensitization and somatic health  
562 complaints. *Scand J Psychol.* 2002;43(2):113–21.

563 18. Rygh LJ, Tjolsen A, Hole K, et al. Cellular memory in spinal  
564 nociceptive circuitry. *Scand J Psychol.* 2002;43(2):153–9.

565 19. Simons DG, Travell J, Simons LE. *Myofascial pain and dysfunc-*  
566 *tion: the trigger point manual.* 2nd ed. Baltimore, MD: Williams  
567 and Wilkins; 1999.

568 20. Gerwin RD, Dommerholt J, Shah JP. An expansion of Simons'  
569 integrated hypothesis of trigger point formation. *Curr Pain*  
570 *Headache Rep.* 2004;8(6):468–75.

571 21. •• Ge HY, Fernandez-de-las-Penas C, Yue SW. Myofascial trigger  
572 points: spontaneous electrical activity and its consequences for  
573 pain induction and propagation. *Chin Med.* 2011;6:13. *Excellent*  
574 *review and scientific update on the parts of the integrated*  
575 *triggerpoint hypothesis: the taut band, local and referred pain,*  
576 *peripheral and central sensitization.*

577 22. Fu Z, Hsieh YL, Hong CZ, et al. Remote subcutaneous needling to  
578 suppress the irritability of myofascial trigger spots: an experimen-  
579 tal study in rabbits. *Evid Based Complement Alternat Med.*  
580 2012;2012:353916.

581 23. Mense S. How Do Muscle Lesions such as Latent and Active  
582 Trigger Points Influence Central Nociceptive Neurons? *J*  
583 *Musculoskeletal Pain.* 2010;18(4):348–53.

584 24. Gerwin R. Myofascial Pain Syndrome: Here We Are, Where Must  
585 We Go? *J Musculoskeletal Pain.* 2010;18(4):329–47.

586 25. Niddam DM, Chan RC, Lee SH, et al. Central representation of  
587 hyperalgesia from myofascial trigger point. *NeuroImage.*  
588 2008;39(3):1299–306.

589 26. •• Chou LW, Kao MJ, Lin JG. Probable mechanisms of needling  
590 therapies for myofascial pain control. *Evid Based Complement*  
591 *Alternat Med.* 2012;2012:705327. ••Citing the several promising

- 592 scientific studies (i.e. electrophysiological, neurophysiological, 658  
 593 and biochemical) that have revealed objective abnormalities in 659  
 594 MTrPs. The analgesic effect of needling is hypothesized to be 660  
 595 related to immune, hormonal, and nervous systems. Compared to 661  
 596 the slow-acting hormonal system, the nervous system acts in a 662  
 597 faster manner. Given these complexities, needling analgesia can- 663  
 598 not be explained by any single mechanism. 664
- 599 27. •• Leung L. Neurophysiological basis of acupuncture-induced 665  
 600 analgesia—an updated review. *J Acupunct Meridian Stud.* 666  
 601 2012;5(6):261–70. This article presents an up-to-date review of 667  
 602 the various neurophysiologic mechanisms that have been proposed 668  
 603 to produce acupuncture-induced analgesia. 669
- 604 28. Zhao ZQ. Neural mechanism underlying acupuncture analgesia. 670  
 605 *Prog Neurobiol.* 2008;85(4):355–75. 671
- 606 29. Hong CZ. Lidocaine injection versus dry needling to myofascial 672  
 607 trigger point. The importance of the local twitch response. *Am J* 673  
 608 *Phys Med Rehabil.* 1994;73(4):256–63. 674
- 609 30. Ceccherelli F, Rigoni MT, Gagliardi G, et al. Comparison of 675  
 610 superficial and deep acupuncture in the treatment of lumbar 676  
 611 myofascial pain: a double-blind randomized controlled study. 677  
 612 *Clin J Pain.* 2002;18(3):149–53. 678
- 613 31. Itoh K, Minakawa Y, Kitakoji H. Effect of acupuncture depth on 679  
 614 muscle pain. *Chin Med.* 2011;6(1):24. 680
- 615 32. Giamberardino MA, Affaitati G, Fabrizio A, et al. Effects of 681  
 616 treatment of myofascial trigger points on the pain of fibromyalgia. 682  
 617 *Curr Pain Headache Rep.* 2011;15(5):393–9. 683
- 618 33. Chen JT, Chung KC, Hou CR, et al. Inhibitory effect of dry 684  
 619 needling on the spontaneous electrical activity recorded from 685  
 620 myofascial trigger spots of rabbit skeletal muscle. *Am J Phys* 686  
 621 *Med Rehabil.* 2000;80(10):729–35. 687
- 622 34. Hsieh YL, Chou LW, Joe YS, et al. Spinal cord mechanism 688  
 623 involving the remote effects of dry needling on the irritability of 689  
 624 myofascial trigger spots in rabbit skeletal muscle. *Arch Phys Med* 690  
 625 *Rehabil.* 2011;92(7):1098–105. 691
- 626 35. Baldry P. *Acupuncture, trigger points and musculoskeletal pain.* 692  
 627 third ed. Churchill Livingstone; 2005. 693
- 628 36. Cagnie B, Barbe T, De Ridder E, et al. The influence of dry 694  
 629 needling of the trapezius muscle on muscle blood flow and oxy- 695  
 630 genation. *J Manipulative Physiol Ther.* 2012;35(9):685–91. 696
- 631 37. Sandberg M, Larsson B, Lindberg LG, et al. Different patterns of 697  
 632 blood flow response in the trapezius muscle following needle 698  
 633 stimulation (acupuncture) between healthy subjects and patients 699  
 634 with fibromyalgia and work-related trapezius myalgia. *Eur J Pain.* 700  
 635 2005;9(5):497–510. 701
- 636 38. Sandberg M, Lundeberg T, Lindberg LG, et al. Effects of acupunc- 702  
 637 ture on skin and muscle blood flow in healthy subjects. *Eur J Appl* 703  
 638 *Physiol.* 2003;90(1–2):114–9. 704
- 639 39. Sandberg M, Lindberg LG, Gerdle B. Peripheral effects of needle 705  
 640 stimulation (acupuncture) on skin and muscle blood flow in fibro- 706  
 641 myalgia. *Eur J Pain.* 2004;8(2):163–71. 707
- 642 40. Kubo K, Yajima H, Takayama M, et al. Changes in blood circula- 708  
 643 tion of the contralateral achilles tendon during and after acupunc- 709  
 644 ture and heating. *Int J Sports Med.* 2011;32(10):807–13. 710
- 645 41. Kubo K, Yajima H, Takayama M, et al. Effects of acupuncture and 711  
 646 heating on blood volume and oxygen saturation of human Achilles 712  
 647 tendon in vivo. *Eur J Appl Physiol.* 2010;109(3):545–50. 713
- 648 42. Ohkubo M, Hamaoka T, Niwayama M, et al. Local increase in 714  
 649 trapezius muscle oxygenation during and after acupuncture. *Dyn* 715  
 650 *Med.* 2009;8:2. 716
- 651 43. Sato A, Sato Y, Shimura M, et al. Calcitonin gene-related peptide 717  
 652 produces skeletal muscle vasodilation following antidromic stimu- 718  
 653 lation of unmyelinated afferents in the dorsal root in rats. 719  
 654 *Neurosci Lett.* 2000;283(2):137–40. 720
- 655 44. •• Hsieh YL, Yang SA, Yang CC, et al. Dry needling at myofascial 721  
 656 trigger spots of rabbit skeletal muscles modulates the biochemicals 722  
 657 associated with pain, inflammation, and hypoxia. *Evid Based* 723  
 658 *Complement Alternat Med.* 2012;2012:342165. The hypothesis 659  
 659 that dry needling at MTrSs can modulate biochemicals associated 660  
 660 with pain, inflammation, and hypoxia depending on the dry need- 661  
 661 ling dosage is supported by this study. data. The findings clarify 662  
 662 the biochemical mechanisms induced by dry needling. Dry need- 663  
 663 ling at the MTrSs modulates various biochemicals associated 664  
 664 with pain, inflammation, and hypoxia in a dose-dependent manner. 665  
 665 45. Shah JP, Phillips T, Danoff JV et al. An in vivo microanalytical 666  
 666 technique for measuring the local biochemical milieu of human 667  
 667 skeletal muscle. *J Appl Physiol.* 2005;(8750–7587 (Print)). 668  
 668 46. Shah JP, Gilliams EA. Uncovering the biochemical milieu of 669  
 669 myofascial trigger points using in vivo microdialysis: an applica- 670  
 670 tion of muscle pain concepts to myofascial pain syndrome. *J* 671  
 671 *Bodyw Mov Ther.* 2008;12(4):371–84. 672
- 672 47. Chiang J, Shen YC, Wang YH, et al. Honokiol protects rats against 673  
 673 eccentric exercise-induced skeletal muscle damage by inhibiting 674  
 674 NF-kappaB induced oxidative stress and inflammation. *Eur J* 675  
 675 *Pharmacol.* 2009;610(1–3):119–27. 676
- 676 48. Melzack R. Myofascial trigger points: relation to acupuncture and 677  
 677 mechanisms of pain. *Arch Phys Med Rehabil.* 1981;62(3):114–7. 678
- 678 49. Chu J, Schwartz I. The muscle twitch in myofascial pain relief: 679  
 679 effects of acupuncture and other needling methods. *Electromyogr* 680  
 680 *Clin Neurophysiol.* 2002;42(5):307–11. 681
- 681 50. Srbely JZ, Dickey JP, Lee D, et al. Dry needle stimulation of 682  
 682 myofascial trigger points evokes segmental anti-nociceptive ef- 683  
 683 fects. *J Rehabil Med.* 2010;42(5):463–8. 684
- 684 51. Hsieh YL, Kao MJ, Kuan TS, et al. Dry needling to a key 685  
 685 myofascial trigger point may reduce the irritability of satellite 686  
 686 MTrPs. *Am J Phys Med Rehabil.* 2007;86(5):397–403. 687
- 687 52. Fernandez-Carero J, Ge HY, Kimura Y, et al. Increased sponta- 688  
 688 neous electrical activity at a latent myofascial trigger point after 689  
 689 nociceptive stimulation of another latent trigger point. *Clin J Pain.* 690  
 690 2010;26(2):138–43. 691
- 691 53. Niddam DM, Chan RC, Lee SH, et al. Central modulation of pain 692  
 692 evoked from myofascial trigger point. *Clin J Pain.* 693  
 693 2007;23(5):440–8. 694
- 694 54. Tobbackx Y, Meeus M, Wauters L et al. Does acupuncture activate 695  
 695 endogenous analgesia in chronic whiplash-associated disorders? A 696  
 696 randomized crossover trial. *Eur J Pain.* 2012. 697
- 697 55. Schliessbach J, van der Klift E, Siegenthaler A, et al. Does acu- 698  
 698 puncture needling induce analgesic effects comparable to diffuse 699  
 699 noxious inhibitory controls? *Evid Based Complement Alternat* 700  
 700 *Med.* 2012;2012:785613. 701
- 701 56. Tsai CT, Hsieh LF, Kuan TS, et al. Remote effects of dry 702  
 702 needling on the irritability of the myofascial trigger point in 703  
 703 the upper trapezius muscle. *Am J Phys Med Rehabil.* 704  
 704 2010;89(2):133–40. 705
- 705 57. Lyby PS, Aslaksen PM, Flaten MA. Variability in placebo analge- 706  
 706 sia and the role of fear of pain—an ERP study. *Pain.* 707  
 707 2011;152(10):2405–12. 708
- 708 58. Kong J, Kaptchuk TJ, Polich G, et al. An fMRI study on the 709  
 709 interaction and dissociation between expectation of pain relief 710  
 710 and acupuncture treatment. *NeuroImage.* 2009;47(3):1066–76. 711
- 711 59. Langevin HM, Wayne PM, Macpherson H, et al. Paradoxes in 712  
 712 acupuncture research: strategies for moving forward. *Evid Based* 713  
 713 *Complement Alternat Med.* 2011;2011:180805. 714
- 714 60. •• Davis RT, Churchill DL, Badger GJ, et al. A new method for 715  
 715 quantifying the needling component of acupuncture treatments. 716  
 716 *Acupunct Med.* 2012;30(2):113–9. *Needling motion and force* 717  
 717 *parameters can be quantified in a treatment-like setting.* 718  
 718 *Needling data can subsequently be analysed, providing an objec-* 719  
 719 *tive method for characterising needling in basic and clinical* 720  
 720 *acupuncture research.* 721
- 721 61. Nijs J, Van Oosterwijck J, De Hertogh W. Rehabilitation of chronic 722  
 722 whiplash: treatment of cervical dysfunctions or chronic pain syn- 723  
 723 drome? *Clin Rheumatol.* 2009;28(3):243–51. 724